Coronary artery stenting has not been shown to prevent deaths or other adverse events compared to medical treatment in patients with stable coronary artery disease. One reason for this is that many people are given stents based on the results of coronary angiography and this test cannot predict who will benefit from the procedure and who will not. Adding an additional test at the time of angiography, the Functional Flow Reserve Test (FFR, also known as the blood-flow test) may add more information on who could benefit from the placement of a stent.
A study released in January 15th’s New England Journal of Medicine found that adding FFR to conventional angiography allowed the researchers to better identify and intervene on those who are more likely to benefit from stenting. This story does a good job of describing the current study and its potential implications for clinical practice. It adequately quantifies the benefits of angiography+FFR, quotes multiple sources, does not engage in disease mongering and accurately describes the novelty of FFR.
The story could have better described the alternatives to angiography with FFR. Clearly angiography alone is the alternative to angiography + FFR. The story briefly mentions stress testing but could have done more to describe the pros and cons of these different testing strategies. Stress testing is underutilized as a first step prior to angiography and it is currently unknown what role it should play in a testing strategy that would include angiography + FFR.
Finally, the story could have done a better job explaining the availability of FFR. The story mentions that the FFR test is used in only 10% of angiographies currently. What is not clear is if that low percentage is due to lack of availability of the technology or practitioners who are trained to use it and where a consumer could expect to find it (in large, academic medical centers only, for example).
Overall, the story did a good job and addressed most of our criteria.
The story adequately describes the cost of performing the test, although it could have been compared to the cost of no stenting.
The story quantifies the mortality rate in the angiography alone versus angiography + FFR group. The story also quantifies the number of stents placed in both groups. The story could have also highlighted the fact that FFR did not reduce the number of people getting stents in the first place.
The story does not mention any harms of FFR. In this context, however, the potential for harms of FFR are insignificant compared to risks of angiography and stenting.
The story adequately describes the design of the current study and notes that more studies are needed to confirm the results.
The story clearly states who this test is appropriate for – those experiencing chest pain symptoms or recovering from a heart attack – and not assymptomatic individuals or those with elevated risk factors for heart disease.
The story quotes multiple experts, including one who is identified as not being associated with the study.
Clearly angiography alone is the alternative to angiography + FFR. The story briefly mentions stress testing but could have done more to describe the pros and cons of these different testing strategies. Stress testing is underutilized as a first step prior to angiography and it is currently unknown what role it should play in a testing strategy that would include angiography + FFR.
The story mentions that the Functional Flow Reserve Test (FFR, also known as the blood-flow test) is used in only 10% of angiographies currently. What is not clear is if that low percentage is due to lack of availability of the technology or practitioners who are trained to use it and where a consumer could expect to find it (in large, academic medical centers only, for example)
The story clearly states that FFR is not a new test but it has not been widely used.
The story quotes more than one expert, one of whom is identified as not being associated with the study. Although the content of the story is very similar to the Stanford press release, it is clear that there was enterprise reporting.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like